The concentrations of amikacin and kanamycin were determined in the serum, gallbladder bile, and gallbladder wall of 20 patients undergoing elective cholecystectomy. Of 20 patients, 14 received 500 mg of amikacin intramuscularly and 6 received 500 mg of kanamycin intramuscularly at various times before surgery. In patients receiving kanamycin, detectable levels appeared in bile within 90 min after drug administration, and in five of six patients concentrations ranged from 1.9 to 23 ytg/ml. Levels of kanamycin in gallbladder wall ranged from 8.0 to 14 .tg/ g. In patients receiving amikacin, detectable levels appeared in bile within 48 min after drug administration and ranged from 1.3 to 7.5 pg/ml in 12 of 14 patients. Levels of amikacin in gallbladder wall ranged from 4.7 to 34 tig/g. The presence of an obstructed cystic duct did not preclude the entry of either antibiotic into gallbladder bile, and this may reflect passage of antibiotic through the gallbladder wall rather than accumulation via bile secretion.
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This report relates the results of a study of the concentration of amikacin and kanamycin in serum, gallbladder bile, and gallbladder wall in a group of 20 patients undergoing cholecystectomy who had received one or the other of these aminoglycosides at various times before surgery.
MATERIALS AND METHODS
Patients and tissue collection. We studied 20 patients who were undergoing cholecystectomy and who had documented cholelithiasis and chronic cholecystitis. These patients ranged from 17 to 65 years of age and from 50 to 77 kg in weight; 16 were female. Preoperative determinations of total bilirubin, alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, blood urea nitrogen, and serum creatinine were carried out in all patients. Except as indicated below, the concentrations of creatinine, blood urea nitrogen, and liver enzymes were normal. One patient in the kanamycin group with alcoholic cirrhosis had a serum bilirubin of 2.4 mg/100 ml. One patient in the amikacin group had a serum bilirubin of 3.0 mg/ 100 ml secondary to choledocholithiasis; four patients in this group had elevated liver enzymes (aspartate, aminotransferase, alanine aminotransferase, and alkaline phosphatase). One patient in the kanamycin group and three patients in the amikacin group had an obstructed cystic duct at surgery.
Preoperatively, 14 patients received 500 mg of amikacin intramuscularly and 6 patients received 500 mg of kanamycin intramuscularly. The exact time of drug administration was noted. One patient in the kanamycin group received two doses of kanamycin, 500 mg each, 10 h and 3 h before surgery. All other patients received one dose of preoperative antibiotic, and no patient received any other antimicrobial agent before surgery. At laparotomy, before manipulation of the gallbladder, 5 ml of bile was withdrawn by puncture of the gallbladder with needle and syringe. Simultaneously, 10 ml of venous blood was drawn from a peripheral vein. In eight patients, specimens of gallbladder wall were taken after removal of the gallbladder. The Bile levels of both antibiotics are of particular note in patients with an obstructed cystic duct found at surgery. In the three such patients in the amikacin group, bile levels ranged from 1.7 to 3.4 4g/ml. In the kanamycin group, in the single such patient studied, the bile level was 23 pg/ml, and the wall level was 14 ,ig/g (this patient had received two preoperative doses of kanamycin). These data show that the presence of an obstructed cystic duct does not preclude entry of either antibiotic into gallbladder bile and suggest that the antibiotic may pass through the gallbladder wall to enter the bile as well as accumulate via bile secretions.
Even with sophisticated contemporary diagnostic and surgical techniques, sepsis frequently complicates the management of patients with biliary disease. We suggest that further studies of aminoglycoside penetration into gallbladder wall and bile are warranted, with emphasis on patients with an obstructed biliary tract.
